Random Massively Parallel Sequencing (rMPS)
Most comprehensively validated and most frequently and routinely employed method worldwide
According to the published data, the rMPS method, which is used in the PrenaTest® among others, is not only the most comprehensively validated method, but also the most frequently and routinely employed method worldwide.
One reason for the preferred use of the rMPS method in routine clinical testing is its high level of reliability. Based on the current data for Sequenom with 250,000 routine tests, the failure rate is currently 1.4%. The failure rate for the PrenaTest® is currently a mere 0.6% (as of Dec. 2014).
The accuracy of the tests also demonstrate how stable rMPS is. Sequenom has reported a sensitivity of 99.29% and a specificity of 99.99% for trisomy 21 (i.e. a false-positive rate of 0.01%) with a positive predictive value (PPV) of 99.04%. LifeCodexx AG has achieved similar values in routine testing. In the case of the PrenaTest®, sensitivity for fetal trisomy 21 is currently 100%, specificity is 99.97% (i.e. the false-positive rate is 0.03%), and the PPV is 98.29%. These values are based on the test results reported by physicians.